COMMUNIQUÉS West-GlobeNewswire

L’Association canadienne de dermatologie, en partenariat avec Mélanome Canada, offrira des dépistages gratuits du cancer de la peau sur la Colline du Parlement
27/05/2026
Cet événement a pour but de souligner l’importance vitale du dépistage précoce du cancer et d’appeler à un meilleur accès aux soins dermatologiques partout au Canada OTTAWA, Ontario, 27 mai 2026 (GLOBE NEWSWIRE) -- [...]
MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
27/05/2026
EscharEx ® Phase III VALUE trial advancing; interim assessment and enrollment completion expected by the end of the first quarter of 2027 First quarter revenue of $1.5 million; full-year 2026 revenue guidance reaffirmed [...]
Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
27/05/2026
Phase 1 data support TNX-1500 as a potentially first-in-class, best-in-class, third-generation anti-CD40L monoclonal antibody for the prevention of kidney transplant rejection Phase 2 investigator-initiated study in [...]
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
27/05/2026
WATERTOWN, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological [...]
BioCryst to Present New HAE Data from ORLADEYO® (berotralstat) and Navenibart at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting
27/05/2026
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioedema (HAE) portfolio [...]
Korro to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
CAMBRIDGE, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA ® ) platform to develop a new [...]
NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Becomes First Commercial Site to Deploy Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
27/05/2026
Deployment at HOPE's West Palm Beach clinic brings AI-powered, sub-millimetric image guidance to the delivery of Transcranial Magnetic Stimulation (TMS) for patients with Major Depressive Disorder and other neurological [...]
Sharps Technology Becomes SkyAI, Inc. with New Ticker Symbol “SKYA”; Establishing Category-defining Agentic Finance Platform Serving Global South
27/05/2026
Rebrand to SkyAI, Inc. to reflect evolution of the business to build a global agentic finance platform Opened operational headquarters in Hong Kong, a global hub for financial technology innovation and a base for [...]
MitoRx Therapeutics to present new preclinical data on MTRX31, its novel mitochondrial-targeted small molecule at the American Diabetes Association’s 2026 Scientific Sessions
27/05/2026
Poster to be presented at ADA 2026 on weight loss induced by MTRX31 in an industry-standard preclinical model of obesity MitoRx Chief Scientific Officer Xavier Jacq to also participate in panel and deliver corporate [...]
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
27/05/2026
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the [...]
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
27/05/2026
Up to $1.3 billion in flexible, non-dilutive capital, including up to $800 million of synthetic royalty and access of up to $500 million in senior corporate debt Combined with company's current total cash of $1.3 [...]
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
27/05/2026
APEX Part B met all primary and secondary endpoints with high statistical significance; mid-dose zumilokibart planned to advance into Phase 3 trials in moderate-to-severe atopic dermatitis (AD) in 2H 2026 Zumilokibart [...]
InnoCare Announces Approval of Orelabrutinib in Australia
27/05/2026
BEIJING, May 27, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that orelabrutinib (HIBRUKA ® ) has [...]
AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026
27/05/2026
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, [...]
Agomab Announces Results of Annual General Meeting
27/05/2026
Antwerp, Belgium, May 27, 2026 – Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced the results of its Annual General Meeting (AGM [...]
Bonito Biosciences and DaltonTx Announce AI-Driven Collaboration to Advance Precision Delivery for Oligotherapeutics
27/05/2026
Collaboration combines Bonito’s proprietary functional delivery data engine and ligand discovery platform with Dalton Tx ’s adaptive AI technology to accelerate precision oligotherapeutic delivery, beginning in the CNS [...]
Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions
27/05/2026
Press release – No. 10 / 2026 Zealand Pharma to Present Data at the American Diabetes Association's 2026 Scientific Sessions Late-breaking Phase 2 ZUPREME-1 data on petrelintide to be featured as ePoster Theater [...]
Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
27/05/2026
Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoir Data on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented [...]
Intravacc Secures French CIR Approval to Support Vaccine R&D Partnerships
27/05/2026
The 2025-2027 approval helps French innovators access Intravacc’s vaccine development, analytical development and cGMP manufacturing services French Ministry approval recognizes Intravacc as a private research [...]

Pages